Diffusely infiltrative low-grade gliomas in adults.

Area of Science:

• Neuro-oncology
• Neurosurgery
• Oncology

Background:

• Diffusely infiltrating low-grade gliomas (LGGs), including astrocytomas, oligodendrogliomas, and mixed oligoastrocytomas (WHO grade 2), present a clinical challenge.
• Routine magnetic resonance imaging (MRI) has increased LGG diagnosis, highlighting the need for clear treatment guidelines.
• The optimal treatment strategy for LGGs remains controversial, making it a complex area in neurooncology.

Purpose of the Study:

• To review the most recent data on the treatment of diffusely infiltrating low-grade gliomas.
• To emphasize evidence-based approaches derived from current clinical trials.
• To discuss the role of laboratory correlative studies in identifying prognostically favorable LGG subsets.

Main Methods:

• Review of current clinical trials and recent data on LGG treatment.
• Analysis of laboratory correlative studies for prognostic markers.
• Emphasis on evidence-based therapeutic strategies.

Main Results:

• Randomized trials are beginning to offer insights into optimal treatment strategies for LGGs.
• Laboratory studies are identifying specific LGG subsets with improved prognosis and treatment response.
• The standard of care for LGGs is still under development, but evidence-based approaches are emerging.

Conclusions:

• Optimal treatment for diffusely infiltrating low-grade gliomas requires further consensus.
• Evidence-based approaches from clinical trials are crucial for guiding LGG management.
• Personalized treatment strategies based on prognostic markers are becoming increasingly important for LGGs.